Prenetics Global Ltd (PRE): Financial results for FY2027
Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. EX 99.1 Prenetics’ IM8 Reports Q3 2026 Revenue Growth of 266% YoY; Earliest Customers Have Returned More Than 3x Their Acquisition Cost in Under Two Years; Reaffirms FY 2026 Total Revenue Guidance of $220–230 Million and FY 2027 IM8 Revenue Guidance of $400 Million+ — Total reven
Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.
How this was made
The 30-second read
Why it matters
The filing is a primary earnings release with quantified Q3 performance, cohort payback claims, and reaffirmed FY2026 and FY2027 revenue guidance, plus an updated second-half Adjusted EBITDA loss range.
Market read
Traders can update positioning around reaffirmed revenue targets, improving CAC and cash flow, and the quantified profitability drag expected in the second half.
What to watch
ARR is an annualized operating metric sensitive to billing timing and cancellations; investors may discount it versus IFRS revenue and scrutinize cohort retention beyond gross profit payback.
Background
Prenetics’ IM8 is positioned as an AI-native direct-to-consumer wellness brand, with cohort economics emphasized in the Q3 2026 release.
Ticker impact
Prenetics reported Q3 2026 revenue $64.1M (+228% YoY) and reaffirmed FY2026 revenue guidance $220–230M and FY2027 IM8 revenue guidance $400M+.
Likely upward bias as investors focus on record IM8 growth, CAC improvement, and positive adjusted free cash flow, tempered by the larger expected second-half EBITDA loss.
The filing provides multiple decision-relevant datapoints: revenue above guidance, IM8 revenue above guidance, CAC declining, adjusted free cash flow turning positive, and a quantified second-half Adjusted EBITDA loss expectation of $30–35M.
Market effects
Reinforces investor appetite for direct-to-consumer wellness models that can show measurable customer payback and cohort economics.
Limited direct regional spillover; primarily affects US-listed consumer health and growth-stock sentiment.
Modest, as the story is company-specific but may influence global comps for subscription wellness and AI-native DTC brands.
Counterpoint
The company’s profitability remains negative, and the reaffirmed FY2027 ramp depends on continued customer retention and marketing efficiency; the second-half EBITDA loss widens to $30–35M.
Key entities
- companyPrenetics Global Ltd
Nasdaq-listed parent of IM8, reporting Q3 2026 results and reaffirming FY2026 and FY2027 guidance.
- brandIM8
Prenetics’ direct-to-consumer wellness brand whose revenue growth and customer cohort economics are central to the release.
- financing_facilityGeneral Catalyst Customer Value Fund
Funding facility referenced for net fundings supporting positive adjusted free cash flow.



